AbbVie Inc. buy Barclays PLC
Start price
27.03.24
/
50%
€166.30
Target price
27.03.25
€180.22
Performance (%)
-9.37%
Price
26.04.24
€149.26
Summary
This prediction is currently active. With a performance of -9.37%, the BUY prediction for AbbVie Inc. by Barclays_PLC is down slightly. Dividends of €1.46 are taken into consideration when calculating the performance. This prediction currently runs until 27.03.25. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| AbbVie Inc. | -4.443% | -4.443% |
| iShares Core DAX® | 2.594% | -1.158% |
| iShares Nasdaq 100 | 3.553% | -1.727% |
| iShares Nikkei 225® | 0.687% | -8.354% |
| iShares S&P 500 | 2.209% | -0.942% |
Comments by Barclays_PLC for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $185.00 to $195.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat